Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions

Christine M. Eischen, Timothy J. Kottke, Luis M. Martins, Guriqbal S. Basi, Jay S. Tung, William C. Earnshaw, Paul J. Leibson, Scott H Kaufmann

Research output: Contribution to journalArticle

246 Citations (Scopus)

Abstract

The Fas/Fas ligand (FasL) pathway is widely involved in apoptotic cell death in lymphoid and nonlymphoid cells. It has recently been postulated that many chemotherapeutic agents also induce cell death by activating the Fas/FasL pathway. In the present study we compared apoptotic pathways induced by anti-Fas or chemotherapeutic agents in the Jurkat human T-cell leukemia line. Immunoblotting showed that treatment of wild-type Jurkat cells with anti-Fas or the topoisomerase II-directed agent etoposide resulted in proteolytic cleavage of precursors for the cysteine-dependent aspartate- directed proteases caspase-3 and caspase-7 and degradation of the caspase substrates poly(ADP-ribose) polymerase (PARP) and lamin B1. Likewise, affinity labeling with N-(N(α)-benzyloxycarbonylglutamyI-N(ε)- biotinyllysyl)aspartic acid [(2,6-dimethyl-benzoyl)oxy]methyl ketone [Z-EK (bio)D-amok] labeled the same five active caspase species after each treatment, suggesting that the same downstream apoptotic pathways have been activated by anti-Fas and etoposide. Treatment with ZB4, an antibody that inhibits Fas-mediated cell death, failed to block etoposide-induced apoptosis, raising the possibility that etoposide does not initiate apoptosis through Fas/FasL interactions. To further explore the relationship between Fas, and chemotherapy induced apoptosis, Fas-resistant Jurkat cells were treated with various chemotherapeutic agents. Multiple independently derived Fas-resistant Jurkat lines underwent apoptosis that was indistinguishable from that of the Fas-sensitive parental cells after treatment with etoposide, doxorubicin, topotecan, cisplatin, methotrexate, staurosporine, or γ- irradiation. These results indicate that antineoplastic treatments induce apoptosis through a Fas-independent pathway even though Fas- and chemotherapy-induced pathways converge on common downstream apoptotic effector molecules.

Original languageEnglish (US)
Pages (from-to)935-943
Number of pages9
JournalBlood
Volume90
Issue number3
StatePublished - Aug 1 1997

Fingerprint

Fas Ligand Protein
Chemotherapy
Etoposide
Apoptosis
Drug Therapy
Cell death
Cell Death
Jurkat Cells
Caspases
Aspartic Acid
Topotecan
Caspase 7
T-Cell Leukemia
Therapeutics
Type II DNA Topoisomerase
Staurosporine
T-cells
Poly(ADP-ribose) Polymerases
Ketones
Immunoblotting

ASJC Scopus subject areas

  • Hematology

Cite this

Eischen, C. M., Kottke, T. J., Martins, L. M., Basi, G. S., Tung, J. S., Earnshaw, W. C., ... Kaufmann, S. H. (1997). Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 90(3), 935-943.

Comparison of apoptosis in wild-type and Fas-resistant cells : Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. / Eischen, Christine M.; Kottke, Timothy J.; Martins, Luis M.; Basi, Guriqbal S.; Tung, Jay S.; Earnshaw, William C.; Leibson, Paul J.; Kaufmann, Scott H.

In: Blood, Vol. 90, No. 3, 01.08.1997, p. 935-943.

Research output: Contribution to journalArticle

Eischen, CM, Kottke, TJ, Martins, LM, Basi, GS, Tung, JS, Earnshaw, WC, Leibson, PJ & Kaufmann, SH 1997, 'Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions', Blood, vol. 90, no. 3, pp. 935-943.
Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC et al. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 1997 Aug 1;90(3):935-943.
Eischen, Christine M. ; Kottke, Timothy J. ; Martins, Luis M. ; Basi, Guriqbal S. ; Tung, Jay S. ; Earnshaw, William C. ; Leibson, Paul J. ; Kaufmann, Scott H. / Comparison of apoptosis in wild-type and Fas-resistant cells : Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. In: Blood. 1997 ; Vol. 90, No. 3. pp. 935-943.
@article{2b1dddb4ea4c4b9aaeea632625bf44dc,
title = "Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions",
abstract = "The Fas/Fas ligand (FasL) pathway is widely involved in apoptotic cell death in lymphoid and nonlymphoid cells. It has recently been postulated that many chemotherapeutic agents also induce cell death by activating the Fas/FasL pathway. In the present study we compared apoptotic pathways induced by anti-Fas or chemotherapeutic agents in the Jurkat human T-cell leukemia line. Immunoblotting showed that treatment of wild-type Jurkat cells with anti-Fas or the topoisomerase II-directed agent etoposide resulted in proteolytic cleavage of precursors for the cysteine-dependent aspartate- directed proteases caspase-3 and caspase-7 and degradation of the caspase substrates poly(ADP-ribose) polymerase (PARP) and lamin B1. Likewise, affinity labeling with N-(N(α)-benzyloxycarbonylglutamyI-N(ε)- biotinyllysyl)aspartic acid [(2,6-dimethyl-benzoyl)oxy]methyl ketone [Z-EK (bio)D-amok] labeled the same five active caspase species after each treatment, suggesting that the same downstream apoptotic pathways have been activated by anti-Fas and etoposide. Treatment with ZB4, an antibody that inhibits Fas-mediated cell death, failed to block etoposide-induced apoptosis, raising the possibility that etoposide does not initiate apoptosis through Fas/FasL interactions. To further explore the relationship between Fas, and chemotherapy induced apoptosis, Fas-resistant Jurkat cells were treated with various chemotherapeutic agents. Multiple independently derived Fas-resistant Jurkat lines underwent apoptosis that was indistinguishable from that of the Fas-sensitive parental cells after treatment with etoposide, doxorubicin, topotecan, cisplatin, methotrexate, staurosporine, or γ- irradiation. These results indicate that antineoplastic treatments induce apoptosis through a Fas-independent pathway even though Fas- and chemotherapy-induced pathways converge on common downstream apoptotic effector molecules.",
author = "Eischen, {Christine M.} and Kottke, {Timothy J.} and Martins, {Luis M.} and Basi, {Guriqbal S.} and Tung, {Jay S.} and Earnshaw, {William C.} and Leibson, {Paul J.} and Kaufmann, {Scott H}",
year = "1997",
month = "8",
day = "1",
language = "English (US)",
volume = "90",
pages = "935--943",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Comparison of apoptosis in wild-type and Fas-resistant cells

T2 - Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions

AU - Eischen, Christine M.

AU - Kottke, Timothy J.

AU - Martins, Luis M.

AU - Basi, Guriqbal S.

AU - Tung, Jay S.

AU - Earnshaw, William C.

AU - Leibson, Paul J.

AU - Kaufmann, Scott H

PY - 1997/8/1

Y1 - 1997/8/1

N2 - The Fas/Fas ligand (FasL) pathway is widely involved in apoptotic cell death in lymphoid and nonlymphoid cells. It has recently been postulated that many chemotherapeutic agents also induce cell death by activating the Fas/FasL pathway. In the present study we compared apoptotic pathways induced by anti-Fas or chemotherapeutic agents in the Jurkat human T-cell leukemia line. Immunoblotting showed that treatment of wild-type Jurkat cells with anti-Fas or the topoisomerase II-directed agent etoposide resulted in proteolytic cleavage of precursors for the cysteine-dependent aspartate- directed proteases caspase-3 and caspase-7 and degradation of the caspase substrates poly(ADP-ribose) polymerase (PARP) and lamin B1. Likewise, affinity labeling with N-(N(α)-benzyloxycarbonylglutamyI-N(ε)- biotinyllysyl)aspartic acid [(2,6-dimethyl-benzoyl)oxy]methyl ketone [Z-EK (bio)D-amok] labeled the same five active caspase species after each treatment, suggesting that the same downstream apoptotic pathways have been activated by anti-Fas and etoposide. Treatment with ZB4, an antibody that inhibits Fas-mediated cell death, failed to block etoposide-induced apoptosis, raising the possibility that etoposide does not initiate apoptosis through Fas/FasL interactions. To further explore the relationship between Fas, and chemotherapy induced apoptosis, Fas-resistant Jurkat cells were treated with various chemotherapeutic agents. Multiple independently derived Fas-resistant Jurkat lines underwent apoptosis that was indistinguishable from that of the Fas-sensitive parental cells after treatment with etoposide, doxorubicin, topotecan, cisplatin, methotrexate, staurosporine, or γ- irradiation. These results indicate that antineoplastic treatments induce apoptosis through a Fas-independent pathway even though Fas- and chemotherapy-induced pathways converge on common downstream apoptotic effector molecules.

AB - The Fas/Fas ligand (FasL) pathway is widely involved in apoptotic cell death in lymphoid and nonlymphoid cells. It has recently been postulated that many chemotherapeutic agents also induce cell death by activating the Fas/FasL pathway. In the present study we compared apoptotic pathways induced by anti-Fas or chemotherapeutic agents in the Jurkat human T-cell leukemia line. Immunoblotting showed that treatment of wild-type Jurkat cells with anti-Fas or the topoisomerase II-directed agent etoposide resulted in proteolytic cleavage of precursors for the cysteine-dependent aspartate- directed proteases caspase-3 and caspase-7 and degradation of the caspase substrates poly(ADP-ribose) polymerase (PARP) and lamin B1. Likewise, affinity labeling with N-(N(α)-benzyloxycarbonylglutamyI-N(ε)- biotinyllysyl)aspartic acid [(2,6-dimethyl-benzoyl)oxy]methyl ketone [Z-EK (bio)D-amok] labeled the same five active caspase species after each treatment, suggesting that the same downstream apoptotic pathways have been activated by anti-Fas and etoposide. Treatment with ZB4, an antibody that inhibits Fas-mediated cell death, failed to block etoposide-induced apoptosis, raising the possibility that etoposide does not initiate apoptosis through Fas/FasL interactions. To further explore the relationship between Fas, and chemotherapy induced apoptosis, Fas-resistant Jurkat cells were treated with various chemotherapeutic agents. Multiple independently derived Fas-resistant Jurkat lines underwent apoptosis that was indistinguishable from that of the Fas-sensitive parental cells after treatment with etoposide, doxorubicin, topotecan, cisplatin, methotrexate, staurosporine, or γ- irradiation. These results indicate that antineoplastic treatments induce apoptosis through a Fas-independent pathway even though Fas- and chemotherapy-induced pathways converge on common downstream apoptotic effector molecules.

UR - http://www.scopus.com/inward/record.url?scp=0030806351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030806351&partnerID=8YFLogxK

M3 - Article

C2 - 9242521

AN - SCOPUS:0030806351

VL - 90

SP - 935

EP - 943

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -